RareResearch.AI
← Back to atlas

A31G

Category 5 — IDR ExclusionConflictingCytoplasmic · predictedEditorial
AlanineGlycine at position 31 · N-terminal intrinsically disordered region (1-86) · WFS1 (Wolframin)

Alanine → Glycine at position 31 in wolframin's N-terminal intrinsically disordered region (IDR). ClinVar carries conflicting classifications. AlphaMissense 0.100 (likely BENIGN). pLDDT 28 — deep IDR. DynaMut2 ΔΔG -0.35 kcal/mol but NOT trustworthy. A Category 5 IDR variant flagged for wet-lab validation.

Interactive 3D Structure

Wild-type reference
Wild-type A31 — native residue, no strong sidechain contacts
Fullscreen ↗
DynaMut2 mutant · A31G
Mutant G31 — energy-minimized; local contact network preserved
Fullscreen ↗

Computational Predictions

DynaMut2 ΔΔG
-0.35kcal/mol
Destabilising — mild
AlphaMissense
0.100
LBen
AlphaFold pLDDT
28
model confidence
Schema
Cat 5
Category 5 — IDR Exclusion

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Associated conditionsInborn genetic diseases; Wolfram syndrome 1
InheritanceInheritance pattern uncertain given conflicting ClinVar classifications. Documented in patients with Wolfram syndrome and inborn genetic diseases.
Population frequency (gnomAD v4)Ultra-rare · AF 0.0070%
cDNA changec.92C>G
ClinVar accessionVCV000215373
Last evaluated2025/09/10 00:00

Observed at very low frequency in gnomAD.

Structural Context

Position 31 sits in wolframin's N-terminal IDR. The pLDDT score of 28 indicates that AlphaFold cannot reliably predict the local conformation — the protein adopts an ensemble of structures in this region rather than a single fold. Neighbor analysis returns only the immediate sequence neighbors (SER32 at 2.5 Å, THR30 at 2.6 Å, LEU33 at 4.6 Å) — the structural signature of IDR.

Replacing alanine with glycine adds backbone flexibility. Glycine permits backbone conformations (especially in the Ramachandran left-handed helix region) that other amino acids cannot adopt. In a folded protein this is sometimes structurally significant. In an IDR, where the protein is already conformationally heterogeneous, the impact is more subtle — the ensemble's accessible conformational space shifts slightly, but no single 'wild-type' geometry is being broken.

DynaMut2's |ΔΔG| of 0.35 kcal/mol is not interpretable as a quantitative claim in this region. AlphaMissense's 0.100 score (well below the 0.564 pathogenic threshold) considers the variant likely benign.

The conflicting ClinVar classifications — some pathogenic, some uncertain — likely reflect that this variant has been observed in patients with Wolfram-spectrum disease but causal contribution has not been firmly established. The mechanism, if pathogenic, would likely involve IDR-mediated phase separation, partner binding through disordered regions, or context-dependent functional disruption — none of which AlphaMissense's training reliably captures.

Amino-acid chemistry
Alanine (A) → Glycine (G) — a small hydrophobic methyl-bearing residue replaced by the smallest amino acid (no side chain). The substitution removes a methyl group and adds backbone flexibility.
Position in the protein
N-terminal intrinsically disordered region (residues 1–86) · position 31 sits in a region with pLDDT 28, deep in IDR territory. The AlphaFold model is not predictive here.

Druggability Assessment

Category 5 — IDR Exclusion. pLDDT = 28 places this variant deep in wolframin's IDR. DynaMut2 stability predictions are not trustworthy here. AlphaMissense's score of 0.100 (likely benign) raises a substantive question about whether the variant is genuinely pathogenic or is a benign variant observed by association.

The Atlas routes Category 5 variants to wet-lab characterization rather than computational drug discovery. For A31G specifically, the recommended next steps are: (1) verify the clinical association with case-by-case review; (2) characterize the IDR's functional role; (3) test the variant in functional assays. Therapeutic strategy decisions should not be made on the current computational data alone.

Why this matters

A31G is one of two IDR-pair Category 5 variants in this batch (with G78R). Both sit in wolframin's N-terminal disordered region, both have AlphaMissense scores in the likely-benign range, both carry conflicting ClinVar classifications. The Atlas appropriately flags these as exclusions from the computational drug discovery pipeline. Pre-atlas analysis might have included them as therapeutic targets; the Atlas's IDR-exclusion logic is what prevents that misallocation of effort.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the A31G PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download A31G PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Region1321 · Interaction with ATP6V1A
Region186 · Disordered